Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. (Q42794620)

7 November 2017

Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. (English)

1 reference

7 November 2017

Jeremy Griggs

1

1 reference

7 November 2017

Jeremy N Skepper

2

1 reference

7 November 2017

Gerry A Smith

3

1 reference

7 November 2017

Kevin M Brindle

4

1 reference

7 November 2017

James C Metcalfe

5

1 reference

7 November 2017

Robin Hesketh

6

1 reference

7 November 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

The American Journal of Pathology

7 November 2017

1 reference

7 November 2017

160

1 reference

7 November 2017

3

1 reference

7 November 2017

1097-1103

1 reference

Targeting tumour vasculature: the development of combretastatin A4.

7 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

The balance between proteinases and inhibitors in a murine model of proliferative retinopathy.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Angiogenesis in cancer and other diseases

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Retinal and choroidal neovascularization

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Antiangiogenic strategies and agents in clinical trials

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

27 May 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

27 May 2018

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964930-9

Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization

7 January 2021

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Potent anti-metastatic activity of combretastatin-A4.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1867165

Blindness caused by diabetic retinopathy

16 August 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964930-9

Synthesis of biologically active polyphenolic glycosides (combretastatin and resveratrol series)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964930-9

Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964930-9

Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9440%2810%2964930-9

Oxygen-induced retinopathy in the mouse

7 January 2021

1 reference

12 December 2020

Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs

1 reference

12 December 2020

Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model

1 reference

12 December 2020

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

1 reference

12 December 2020

10.1016/S0002-9440(10)64930-9

Identifiers

DOI

1 reference

7 November 2017

1 reference

7 November 2017

PubMed publication ID

11891206

1 reference